Filter results
You can narrow down the results using the filters
Audience
Topics
Our work
Diseases
10852 results
-
Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Pompe disease – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for infantile-onset or late-onset Pompe disease under the Life Saving Drugs Program. -
Life Saving Drugs Program – Pompe disease – Patient test results spreadsheets
Treating physicians use the relevant spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Pompe disease – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Pompe disease for the first time, or after a break. -
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type II (MPS II) under the Life Saving Drugs Program. -
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type I (MPS I) under the Life Saving Drugs Program. -
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for hereditary tyrosinaemia (type 1) under the Life Saving Drugs Program. -
Life Saving Drugs Program – Late infantile Batten disease (CLN2)
These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for late-infantile onset Batten disease under the Life Saving Drugs Program. -
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS II for the first time, or after a break. -
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS I for the first time, or after a break. -
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D) – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access certain medications for infantile onset lysosomal acid lipase deficiency (LAL-D) under the Life Saving Drugs Program. -
Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type VI (MPS VI) under the Life Saving Drugs Program. -
Life Saving Drugs Program – Late infantile Batten disease (CLN2 disease) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Batten disease for the first time, or after a break. -
Life Saving Drugs Program – Late-Infantile Onset Batten disease (CLN2 disease) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Gaucher disease (type 1) – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access certain medications for Gaucher disease (type 1) under the Life Saving Drugs Program. -
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for hereditary tyrosinaemia (type 1) for the first time, or after a break. -
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Gaucher disease (type 1) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Gaucher disease for the first time, or after a break. -
Life Saving Drugs Program – Gaucher disease (type 1) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for hereditary tyrosinaemia (type 1). -
Life Saving Drugs Program – Spreadsheet for infantile-onset lysosomal acid-lipase deficiency disease (LAL-D)
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
New Aged Care Act Rules consultation – Release 1 – Service list
The Stage 1 release for the consultation on the New Aged Care Act Rules contains the service list. The service list outlines the care and services that will be available to older people under the new laws. -
Aged Care Worker Award Wage Increase – Stage 3 – Questions and answers
This document provides answers to questions about the Fair Work Commission’s Stage 3 decision on the Aged Care Work Value Case which will deliver further increases to award wages for many aged care workers from 1 January 2025.